HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.

Abstract
The aim of the present study was to evaluate an intensive chemotherapy regimen in patients with diffuse large B-cell lymphoma and poor prognosis, as presence of high- or high-intermediate clinical risk, bulky disease, high levels of beta 2 microgloblin, and more than two extranodal sites of involvement at diagnosis. One hundred previously untreated patients were treated with an intensive CEOP-Bleo regimen with increased doses of cyclophosphamide (1000 mg/m(2)) and epirubicin (120 mg/m(2)) in each cycle. Granulocyte colony-stimulating factors was employed to ameliorate severe granulocytopenia. Complete response was achieved in 79 cases (79%). With a median follow-up of 32.3 mo (range 10-45 mo) only seven patients have relapsed. Thus, actuarial curves at 3 yr, showed that event-free survival was 72%. Five died secondary to tumor progression, actuarial curves at 3-yr for overall survival were 75%. Toxicity was mild, granulocytopenia grade III or IV were observed in the 46% of the cycles; infection-related granulocytopenia was observed in 17%, but no fatality due to therapy was observed. Cardiac toxicity was mild, only seven patients showed a drop in left ejection ventricular function, but no symptomatic heart failure has been observed. The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma.
AuthorsAgustin Avilés, M Jesús Nambo, Natividad Neri, Alejandra Talavera, Claudia Castañeda, Edgar Murillo, Sergio Cleto, Judith Huerta-Guzmán
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 21 Issue 3 Pg. 269-72 ( 2004) ISSN: 1357-0560 [Print] United States
PMID15456955 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Agents, Phytogenic
  • Bleomycin
  • Epirubicin
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage)
  • Antimetabolites, Antineoplastic (administration & dosage)
  • Antineoplastic Agents, Alkylating (administration & dosage)
  • Antineoplastic Agents, Hormonal (administration & dosage)
  • Antineoplastic Agents, Phytogenic (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Bleomycin (administration & dosage)
  • Cyclophosphamide (administration & dosage, therapeutic use)
  • Doxorubicin (administration & dosage, therapeutic use)
  • Epirubicin (administration & dosage)
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, B-Cell (drug therapy, mortality)
  • Male
  • Middle Aged
  • Prednisone (administration & dosage, therapeutic use)
  • Prognosis
  • Risk Factors
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • Vincristine (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: